Search

Intake unconfirmed. Checked 2026-10-03. ICU pneumonia caused by multidrug-resistant organisms; age 18–95 and bacteria susceptible to selected phages in the registry eligibility criteria. Shenzhen; China treating-center CN ChiCTR2500104137 l

Intake unconfirmed. Checked 2026-10-03. Single-arm difficult-to-treat bacterial infection study, planned 240 participants, matched phages, non-IV routes including nebulization, topical, local injection or perfusion. Shanghai; China treating

Intake unconfirmed. Checked 2026-10-03. Randomized personalized phage treatment study for multidrug-resistant bacterial skin infections; separate July 2026 company announcement describes a joint phage bank. Xi’an; China treating-center CN N

Intake unconfirmed. Checked 2026-10-03. Phage treatment research for orthopedic implant-associated infections. Hangzhou; China treating-center CN NCT07533292 is Not yet recruiting; last posted update 2026-04-16, estimated start 2026-04-05.

Intake unconfirmed. Checked 2026-10-03. Single-arm personalized phage study for difficult-to-treat bacterial infections; requires a matched lytic phage and a feasible non-intravenous route. Antibiotic-controlled infections and cases with IV

Research/development. Checked 2026-10-03. Official August 2026 regulator meeting describes earlier clinical research with Georgia and ongoing product/regulatory development; current commercial focus mentioned includes animal dermatologic in

Intake unconfirmed. Checked 2026-10-03. PJI phage supply: historical 2024 case and two S. aureus candidate patients announced September 2025, subject to ethics, Health Canada and Environment Canada approvals. Winnipeg, Manitoba; Canada comp

Case-by-case; Official referral/inquiry route. Checked 2026-10-04. Selected-case phage treatment for difficult bacterial infections, including bone and joint infections. The hospital announced its Institute for Phage Medicine on September 2

Intake unconfirmed. Checked 2026-10-04. Phage production collaboration with the I2SysBio laboratory; this is a supplier record, not a treatment clinic. Valencia, Spain supplier ES The company publishes a general contact route on its officia

Case-by-case; Intake unconfirmed. Checked 2026-10-04. Reported nebulized phage treatment in a cystic fibrosis respiratory-infection case, in collaboration with I2SysBio and Yale. Valencia, Spain treating-center ES A June 2024 University of

Intake unconfirmed. Checked 2026-10-04. Institutional reports describe phage preparation for compassionate treatments, including respiratory infections in people with cystic fibrosis. Valencia, Spain supplier ES Produces therapeutic phages

Research/development. Checked 2026-10-04. Institutional research group studying phage therapy, phage-host interactions and approaches to antibiotic-resistant infections. A Coruña, Spain research-only ES Research group; contact the group to

Case-by-case; Intake unconfirmed. Checked 2026-10-04. Reported nebulized phage treatment in a cystic fibrosis respiratory-infection case, in collaboration with I2SysBio and Yale. Seville, Spain treating-center ES A June 2024 University of V

Intake unconfirmed. Checked 2026-10-03. Nebulized phages for P. aeruginosa ventilator-associated pneumonia; multicenter randomized study. Paris coordinating center; French ICU sites; France network FR Registry lists central AP-HP study cont

Intake unconfirmed. Checked 2026-10-03. Recurrent urinary tract infections; REPhRAME plans engineered E. coli phages followed by microbiota transfer. Zurich; Switzerland treating-center CH Balgrist announces a five-year EU-funded program be

Provider-listed inquiry route. Checked 2026-10-03. Human phage products targeting bacterial pathogens including staphylococci, E. coli, enterococci, Proteus, streptococci and P. aeruginosa. Tbilisi; Georgia supplier GE Official site describ

Intake unconfirmed. Checked 2026-10-03. PhagoFlow produced P. aeruginosa phages and treated wound, urinary, ear and respiratory infections in individual attempts. Berlin; Germany treating-center DE Completed research infrastructure supporte

Intake unconfirmed. Checked 2026-10-03. S. aureus phages for infected diabetic foot ulcers in a randomized study; French sites. Nîmes / Le Grau-du-Roi coordinating sites; France network FR CTIS currently lists recruitment in France; study c

Research/development. Checked 2026-10-03. Phage and lysin research, experimental development and rare exceptional clinical use context. Lausanne; Switzerland research-only CH Official laboratory contact is for research; no dedicated patient

Provider-listed inquiry route. Checked 2026-10-03. Company describes six marketed standard phage preparations and custom development for human, veterinary and environmental use. Tbilisi; Georgia supplier GE Manufacturer contact info@phage.g